Regeneron, Mammoth Partner To Pursue Next-Generation CRISPR-Based Gene Editing For Multiple Diseases; Mammoth To Receive $100M Total Upfront Payment And Equity Investment

Regeneron Pharmaceuticals, Inc. -0.74%

Regeneron Pharmaceuticals, Inc.

REGN

741.29

-0.74%

Under the terms of the agreement, Mammoth will receive $100 million inclusive of $95 million in equity investment at signing, and an upfront payment, and is eligible to receive up to $370 million per target in development, regulatory and commercial milestone payments, and royalty rates ranging from single digits to mid-teens on future net sales of all collaboration products.

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via